Carvajal RD - Search Results

1

Advances in the clinical management of uveal melanoma.

Carvajal RD, Sacco JJ, Jager MJ, Eschelman DJ, Olofsson Bagge R, Harbour JW, Chieng ND, Patel SP, Joshua AM, Piperno-Neumann S. Carvajal RD, et al. Nat Rev Clin Oncol. 2023 Feb;20(2):99-115. doi: 10.1038/s41571-022-00714-1. Epub 2023 Jan 4. Nat Rev Clin Oncol. 2023. PMID: 36600005 Review.

2

Therapeutic implications of the emerging molecular biology of uveal melanoma.

Patel M, Smyth E, Chapman PB, Wolchok JD, Schwartz GK, Abramson DH, Carvajal RD. Patel M, et al. Among authors: carvajal rd. Clin Cancer Res. 2011 Apr 15;17(8):2087-100. doi: 10.1158/1078-0432.CCR-10-3169. Epub 2011 Mar 28. Clin Cancer Res. 2011. PMID: 21444680

3

Characterization of computed tomography scan abnormalities in patients with biopsy-proven hepatic metastases from uveal melanoma.

Patel M, Winston CB, Marr BP, Carvajal RD, Schwartz GK, Wolchok J, Busam K, Abramson DH. Patel M, et al. Among authors: carvajal rd. Arch Ophthalmol. 2011 Dec;129(12):1576-82. doi: 10.1001/archophthalmol.2011.263. Arch Ophthalmol. 2011. PMID: 22159677

4

Mucosal melanoma: pathogenesis, clinical behavior, and management.

Postow MA, Hamid O, Carvajal RD. Postow MA, et al. Among authors: carvajal rd. Curr Oncol Rep. 2012 Oct;14(5):441-8. doi: 10.1007/s11912-012-0244-x. Curr Oncol Rep. 2012. PMID: 22661391 Review.

5

Locoregional lymphadenectomy in the surgical management of anorectal melanoma.

Perez DR, Trakarnsanga A, Shia J, Nash GM, Temple LK, Paty PB, Guillem JG, Garcia-Aguilar J, Bello D, Ariyan C, Carvajal RD, Weiser MR. Perez DR, et al. Among authors: carvajal rd. Ann Surg Oncol. 2013 Jul;20(7):2339-44. doi: 10.1245/s10434-012-2812-6. Epub 2013 Jan 18. Ann Surg Oncol. 2013. PMID: 23328972 Free PMC article.

6

Surveillance options for patients with uveal melanoma following definitive management.

Francis JH, Patel SP, Gombos DS, Carvajal RD. Francis JH, et al. Among authors: carvajal rd. Am Soc Clin Oncol Educ Book. 2013:382-7. doi: 10.14694/EdBook_AM.2013.33.382. Am Soc Clin Oncol Educ Book. 2013. PMID: 23714555 Free article. Review.

7

Prognosis of acral melanoma: a series of 281 patients.

Bello DM, Chou JF, Panageas KS, Brady MS, Coit DG, Carvajal RD, Ariyan CE. Bello DM, et al. Among authors: carvajal rd. Ann Surg Oncol. 2013 Oct;20(11):3618-25. doi: 10.1245/s10434-013-3089-0. Epub 2013 Jul 10. Ann Surg Oncol. 2013. PMID: 23838913 Clinical Trial.

8

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.

Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD. Luke JJ, et al. Among authors: carvajal rd. Cancer. 2013 Oct 15;119(20):3687-95. doi: 10.1002/cncr.28282. Epub 2013 Aug 2. Cancer. 2013. PMID: 23913718 Free PMC article.

9

Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells.

Ambrosini G, Khanin R, Carvajal RD, Schwartz GK. Ambrosini G, et al. Among authors: carvajal rd. Mol Cancer Ther. 2014 Aug;13(8):2073-80. doi: 10.1158/1535-7163.MCT-14-0095. Epub 2014 Jun 4. Mol Cancer Ther. 2014. PMID: 24899684

10

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.

Carvajal RD, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Kudchadkar RR, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Doyle A, Ancell K, Panageas KS, Bluth M, Hedvat C, Erinjeri J, Ambrosini G, Marr B, Abramson DH, Dickson MA, Wolchok JD, Chapman PB, Schwartz GK. Carvajal RD, et al. JAMA. 2014 Jun 18;311(23):2397-405. doi: 10.1001/jama.2014.6096. JAMA. 2014. PMID: 24938562 Free PMC article. Clinical Trial.

11

Biology of advanced uveal melanoma and next steps for clinical therapeutics.

Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, Gutkind JS, Bowcock AM, Streicher HZ, Patel PM, Sato T, Sossman JA, Sznol M, Welch J, Thurin M, Selig S, Flaherty KT, Carvajal RD. Luke JJ, et al. Among authors: carvajal rd. Pigment Cell Melanoma Res. 2015 Mar;28(2):135-47. doi: 10.1111/pcmr.12304. Epub 2014 Sep 1. Pigment Cell Melanoma Res. 2015. PMID: 25113308 Free PMC article. Review.

12

GNAQ and GNA11 mutations in uveal melanoma.

Shoushtari AN, Carvajal RD. Shoushtari AN, et al. Among authors: carvajal rd. Melanoma Res. 2014 Dec;24(6):525-34. doi: 10.1097/CMR.0000000000000121. Melanoma Res. 2014. PMID: 25304237 Review.

13

Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line.

Yu X, Ambrosini G, Roszik J, Eterovic AK, Stempke-Hale K, Seftor EA, Chattopadhyay C, Grimm E, Carvajal RD, Hendrix MJ, Hodi FS, Schwartz GK, Woodman SE. Yu X, et al. Among authors: carvajal rd. Pigment Cell Melanoma Res. 2015 May;28(3):357-9. doi: 10.1111/pcmr.12345. Epub 2015 Mar 23. Pigment Cell Melanoma Res. 2015. PMID: 25515650 No abstract available.

14

Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).

Carvajal RD, Schwartz GK, Mann H, Smith I, Nathan PD. Carvajal RD, et al. BMC Cancer. 2015 Jun 10;15:467. doi: 10.1186/s12885-015-1470-z. BMC Cancer. 2015. PMID: 26059332 Free PMC article. Clinical Trial.

15

Treatment of Uveal Melanoma.

Shoushtari AN, Carvajal RD. Shoushtari AN, et al. Among authors: carvajal rd. Cancer Treat Res. 2016;167:281-93. doi: 10.1007/978-3-319-22539-5_12. Cancer Treat Res. 2016. PMID: 26601868 Review.

16

Clinical Management of Uveal and Conjunctival Melanoma.

Blum ES, Yang J, Komatsubara KM, Carvajal RD. Blum ES, et al. Among authors: carvajal rd. Oncology (Williston Park). 2016 Jan;30(1):29-32, 34-43, 48. Oncology (Williston Park). 2016. PMID: 26791842 Free article. Review.

17

Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives.

Komatsubara KM, Manson DK, Carvajal RD. Komatsubara KM, et al. Among authors: carvajal rd. Future Oncol. 2016 Jun;12(11):1331-44. doi: 10.2217/fon-2015-0075. Epub 2016 Apr 5. Future Oncol. 2016. PMID: 27044592 Review.

18

Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.

Kuk D, Shoushtari AN, Barker CA, Panageas KS, Munhoz RR, Momtaz P, Ariyan CE, Brady MS, Coit DG, Bogatch K, Callahan MK, Wolchok JD, Carvajal RD, Postow MA. Kuk D, et al. Among authors: carvajal rd. Oncologist. 2016 Jul;21(7):848-54. doi: 10.1634/theoncologist.2015-0522. Epub 2016 Jun 10. Oncologist. 2016. PMID: 27286787 Free PMC article.

19

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.

Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ. Algazi AP, et al. Among authors: carvajal rd. Cancer. 2016 Nov 15;122(21):3344-3353. doi: 10.1002/cncr.30258. Epub 2016 Aug 17. Cancer. 2016. PMID: 27533448 Free PMC article.

20

Metastatic disease from uveal melanoma: treatment options and future prospects.

Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Carvajal RD, et al. Br J Ophthalmol. 2017 Jan;101(1):38-44. doi: 10.1136/bjophthalmol-2016-309034. Epub 2016 Aug 29. Br J Ophthalmol. 2017. PMID: 27574175 Free PMC article. Review.

21

Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.

Atkinson TM, Hay JL, Shoushtari A, Li Y, Paucar DJ, Smith SC, Kudchadkar RR, Doyle A, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Marr B, Abramson DH, Dickson MA, Schwartz GK, Carvajal RD. Atkinson TM, et al. Among authors: carvajal rd. J Cancer Res Clin Oncol. 2017 Mar;143(3):439-445. doi: 10.1007/s00432-016-2318-x. Epub 2016 Dec 5. J Cancer Res Clin Oncol. 2017. PMID: 27921276 Free PMC article. Clinical Trial.

22

Update on the treatment of uveal melanoma.

Carvajal RD. Carvajal RD. Clin Adv Hematol Oncol. 2016 Oct;14(10):768-770. Clin Adv Hematol Oncol. 2016. PMID: 27930627 No abstract available.

23

Adopting a new stance on immunotherapy for uveal melanoma.

Komatsubara KM, Carvajal RD. Komatsubara KM, et al. Among authors: carvajal rd. Lancet Oncol. 2017 Jun;18(6):702-704. doi: 10.1016/S1470-2045(17)30254-1. Epub 2017 Apr 7. Lancet Oncol. 2017. PMID: 28395881 No abstract available.

24

Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.

Komatsubara KM, Carvajal RD. Komatsubara KM, et al. Among authors: carvajal rd. Curr Oncol Rep. 2017 Jul;19(7):45. doi: 10.1007/s11912-017-0606-5. Curr Oncol Rep. 2017. PMID: 28508938 Review.

25

Treatment of uveal melanoma: where are we now?

Yang J, Manson DK, Marr BP, Carvajal RD. Yang J, et al. Among authors: carvajal rd. Ther Adv Med Oncol. 2018 Feb 21;10:1758834018757175. doi: 10.1177/1758834018757175. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 29497459 Free PMC article. Review.

26

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).

Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, Piulats JM, Wolter P, Cocquyt V, Chmielowski B, Evans TRJ, Gastaud L, Linette G, Berking C, Schachter J, Rodrigues MJ, Shoushtari AN, Clemett D, Ghiorghiu D, Mariani G, Spratt S, Lovick S, Barker P, Kilgour E, Lai Z, Schwartz GK, Nathan P. Carvajal RD, et al. J Clin Oncol. 2018 Apr 20;36(12):1232-1239. doi: 10.1200/JCO.2017.74.1090. Epub 2018 Mar 12. J Clin Oncol. 2018. PMID: 29528792 Free article. Clinical Trial.

27

The Need for Neddylation: A Key to Achieving NED in Uveal Melanoma.

Yang J, Hamid O, Carvajal RD. Yang J, et al. Among authors: carvajal rd. Clin Cancer Res. 2018 Aug 1;24(15):3477-3479. doi: 10.1158/1078-0432.CCR-18-0020. Epub 2018 Apr 2. Clin Cancer Res. 2018. PMID: 29610291 Free PMC article.

28

Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma.

Chua V, Orloff M, Teh JL, Sugase T, Liao C, Purwin TJ, Lam BQ, Terai M, Ambrosini G, Carvajal RD, Schwartz G, Sato T, Aplin AE. Chua V, et al. Among authors: carvajal rd. EMBO Mol Med. 2019 Feb;11(2):e9081. doi: 10.15252/emmm.201809081. EMBO Mol Med. 2019. PMID: 30610113 Free PMC article.

29

Proceedings of the Association for Research in Vision and Ophthalmology and Champalimaud Foundation Ocular Oncogenesis and Oncology Conference.

Smith JR, Pe'er J, Belfort RN, Cardoso F, Carvajal RD, Carvalho C, Coupland SE, Desjardins L, Francis JH, Gallie BL, Gombos DS, Grossniklaus HE, Heegaard S, Jager MJ, Kaliki S, Ksander BR, Maeurer M, Moreno E, Pulido JS, Ryll B, Singh AD, Zhao J, Parreira A, Wilson DJ, O'Brien JM. Smith JR, et al. Among authors: carvajal rd. Transl Vis Sci Technol. 2018 Jan 9;8(1):9. doi: 10.1167/tvst.8.1.9. eCollection 2019 Jan. Transl Vis Sci Technol. 2018. PMID: 30652059 Free PMC article.

30

KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development.

Meng D, Carvajal RD. Meng D, et al. Among authors: carvajal rd. Am J Clin Dermatol. 2019 Jun;20(3):315-323. doi: 10.1007/s40257-018-0414-1. Am J Clin Dermatol. 2019. PMID: 30707374 Review.

31

Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.

Ambrosini G, Do C, Tycko B, Realubit RB, Karan C, Musi E, Carvajal RD, Chua V, Aplin AE, Schwartz GK. Ambrosini G, et al. Among authors: carvajal rd. Cancer Res. 2019 May 1;79(9):2415-2425. doi: 10.1158/0008-5472.CAN-18-3177. Epub 2019 Mar 18. Cancer Res. 2019. PMID: 30885979 Free PMC article.

32

Conjunctival Melanoma: Current Treatments and Future Options.

Grimes JM, Shah NV, Samie FH, Carvajal RD, Marr BP. Grimes JM, et al. Among authors: carvajal rd. Am J Clin Dermatol. 2020 Jun;21(3):371-381. doi: 10.1007/s40257-019-00500-3. Am J Clin Dermatol. 2020. PMID: 31965542 Review.

33

Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071.

Piperno-Neumann S, Larkin J, Carvajal RD, Luke JJ, Schwartz GK, Hodi FS, Sablin MP, Shoushtari AN, Szpakowski S, Chowdhury NR, Brannon AR, Ramkumar T, de Koning L, Derti A, Emery C, Yerramilli-Rao P, Kapiteijn E. Piperno-Neumann S, et al. Among authors: carvajal rd. Mol Cancer Ther. 2020 Apr;19(4):1031-1039. doi: 10.1158/1535-7163.MCT-19-0098. Epub 2020 Feb 6. Mol Cancer Ther. 2020. PMID: 32029634 Clinical Trial.

34

Uveal melanoma.

Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern MH, Carvajal RD, Belfort RN, Jia R, Shields JA, Damato BE. Jager MJ, et al. Among authors: carvajal rd. Nat Rev Dis Primers. 2020 Apr 9;6(1):24. doi: 10.1038/s41572-020-0158-0. Nat Rev Dis Primers. 2020. PMID: 32273508 Review.

35

Novel Approaches to the Systemic Management of Uveal Melanoma.

Khan S, Carvajal RD. Khan S, et al. Among authors: carvajal rd. Curr Oncol Rep. 2020 Jul 28;22(10):104. doi: 10.1007/s11912-020-00965-0. Curr Oncol Rep. 2020. PMID: 32725406 Review.

36

The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019).

Chua V, Mattei J, Han A, Johnston L, LiPira K, Selig SM, Carvajal RD, Aplin AE, Patel SP. Chua V, et al. Among authors: carvajal rd. Clin Cancer Res. 2021 Jan 1;27(1):28-33. doi: 10.1158/1078-0432.CCR-20-2536. Epub 2020 Oct 15. Clin Cancer Res. 2021. PMID: 33060121 Free PMC article.

37

Dual Immunological Checkpoint Blockade for Uveal Melanoma.

Khan S, Carvajal RD. Khan S, et al. Among authors: carvajal rd. J Clin Oncol. 2021 Feb 20;39(6):554-556. doi: 10.1200/JCO.20.03274. Epub 2021 Jan 8. J Clin Oncol. 2021. PMID: 33417487 No abstract available.

38

Multiregional genetic evolution of metastatic uveal melanoma.

Rodriguez DA, Yang J, Durante MA, Shoushtari AN, Moschos SJ, Wrzeszczynski KO, Harbour JW, Carvajal RD. Rodriguez DA, et al. Among authors: carvajal rd. NPJ Genom Med. 2021 Aug 16;6(1):70. doi: 10.1038/s41525-021-00233-5. NPJ Genom Med. 2021. PMID: 34400647 Free PMC article.

39

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.

Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, Joshua AM, Sacco JJ, Shoushtari AN, Orloff M, Piulats JM, Milhem M, Salama AKS, Curti B, Demidov L, Gastaud L, Mauch C, Yushak M, Carvajal RD, Hamid O, Abdullah SE, Holland C, Goodall H, Piperno-Neumann S; IMCgp100-202 Investigators. Nathan P, et al. Among authors: carvajal rd. N Engl J Med. 2021 Sep 23;385(13):1196-1206. doi: 10.1056/NEJMoa2103485. N Engl J Med. 2021. PMID: 34551229 Free article. Clinical Trial.

40

Uveal Melanoma Exosomes Induce a Prometastatic Microenvironment through Macrophage Migration Inhibitory Factor.

Ambrosini G, Rai AJ, Carvajal RD, Schwartz GK. Ambrosini G, et al. Among authors: carvajal rd. Mol Cancer Res. 2022 Apr 1;20(4):661-669. doi: 10.1158/1541-7786.MCR-21-0526. Mol Cancer Res. 2022. PMID: 34992145 Free article.

41

Author Correction: Uveal melanoma.

Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern MH, Carvajal RD, Belfort RN, Jia R, Shields JA, Damato BE. Jager MJ, et al. Among authors: carvajal rd. Nat Rev Dis Primers. 2022 Jan 17;8(1):4. doi: 10.1038/s41572-022-00339-9. Nat Rev Dis Primers. 2022. PMID: 35039549 No abstract available.

42

Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors.

Liu AW, Wei AZ, Maniar AB, Carvajal RD. Liu AW, et al. Among authors: carvajal rd. Expert Opin Biol Ther. 2022 Aug;22(8):997-1004. doi: 10.1080/14712598.2022.2031970. Epub 2022 Feb 2. Expert Opin Biol Ther. 2022. PMID: 35060440 Review.

43

Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Chen LN, Carvajal RD. Chen LN, et al. Among authors: carvajal rd. Expert Rev Anticancer Ther. 2022 Oct;22(10):1017-1027. doi: 10.1080/14737140.2022.2124971. Epub 2022 Sep 19. Expert Rev Anticancer Ther. 2022. PMID: 36102132 Free PMC article. Review.

44

Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy.

Khan S, Lutzky J, Shoushtari AN, Jeter J, Marr B, Olencki TE, Cebulla CM, Abdel-Rahman M, Harbour JW, Sender N, Nesson A, Singh-Kandah S, Hernandez S, King J, Katari MS, Dimapanat L, Izard S, Ambrosini G, Surriga O, Rai AJ, Chiuzan C, Schwartz GK, Carvajal RD. Khan S, et al. Among authors: carvajal rd. Front Oncol. 2022 Aug 29;12:976837. doi: 10.3389/fonc.2022.976837. eCollection 2022. Front Oncol. 2022. PMID: 36106113 Free PMC article.

45

Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases.

Wei AZ, Uriel M, Porcu A, Manos MP, Mercurio AC, Caplan MM, Hulse L, Seedor RS, Holovatska M, Francis J, Khan SA, McDonnell DE, Bogomolny D, Sato T, Marr BP, Haq R, Orloff M, Shoushtari A, Carvajal RD. Wei AZ, et al. Among authors: carvajal rd. Front Oncol. 2022 Sep 8;12:961517. doi: 10.3389/fonc.2022.961517. eCollection 2022. Front Oncol. 2022. PMID: 36212499 Free PMC article.

46

Intermittent MEK inhibition for the treatment of metastatic uveal melanoma.

Khan S, Patel SP, Shoushtari AN, Ambrosini G, Cremers S, Lee S, Franks L, Singh-Kandah S, Hernandez S, Sender N, Vuolo K, Nesson A, Mundi P, Izar B, Schwartz GK, Carvajal RD. Khan S, et al. Among authors: carvajal rd. Front Oncol. 2022 Sep 29;12:975643. doi: 10.3389/fonc.2022.975643. eCollection 2022. Front Oncol. 2022. PMID: 36249046 Free PMC article.

47

A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma.

Bauer S, Larkin J, Hodi FS, Stephen F, Kapiteijn EHW, Schwartz GK, Calvo E, Yerramilli-Rao P, Piperno-Neumann S, Carvajal RD. Bauer S, et al. Among authors: carvajal rd. Front Oncol. 2023 Jun 9;12:975642. doi: 10.3389/fonc.2022.975642. eCollection 2022. Front Oncol. 2023. PMID: 37359242 Free PMC article.

48

Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA).

Wei AZ, Chen LN, Orloff M, Ariyan CE, Asgari M, Barker CA, Buchbinder E, Chandra S, Couts K, Frumovitz MM, Futreal A, Gershenwald JE, Hanna EY, Izar B, LeBlanc AK, Leitao MM Jr, Lipson EJ, Liu D, McCarter M, McQuade JL, Najjar Y, Rapisuwon S, Selig S, Shoushtari AN, Yeh I, Schwartz GK, Guo J, Patel SP, Carvajal RD. Wei AZ, et al. Among authors: carvajal rd. Pigment Cell Melanoma Res. 2023 Nov;36(6):542-556. doi: 10.1111/pcmr.13139. Epub 2023 Oct 7. Pigment Cell Melanoma Res. 2023. PMID: 37804122

49

Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.

Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, Schlaak M, Butler MO, Sullivan RJ, Dummer R, Kirkwood JM, Orloff M, Sacco JJ, Ochsenreither S, Joshua AM, Gastaud L, Curti B, Piulats JM, Salama AKS, Shoushtari AN, Demidov L, Milhem M, Chmielowski B, Kim KB, Carvajal RD, Hamid O, Collins L, Ranade K, Holland C, Pfeiffer C, Nathan P. Hassel JC, et al. Among authors: carvajal rd. N Engl J Med. 2023 Dec 14;389(24):2256-2266. doi: 10.1056/NEJMoa2304753. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870955 Free PMC article. Clinical Trial.

50

Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma.

Fahmy LM, Schreidah CM, McDonnell DE, Carvajal RD, Magro CM, Geskin LJ. Fahmy LM, et al. Among authors: carvajal rd. Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993. Dermatol Online J. 2023. PMID: 38478664 Free article.

51

Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma.

Sacco JJ, Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi A, Hernandez-Aya L, Nathan P, Hamid O, Piulats JM, Rioth M, Johnson DB, Luke JJ, Espinosa E, Leyvraz S, Collins L, Holland C, Sato T. Sacco JJ, et al. Among authors: carvajal rd. J Immunother Cancer. 2024 Jun 6;12(6):e009028. doi: 10.1136/jitc-2024-009028. J Immunother Cancer. 2024. PMID: 38844408 Free PMC article. Clinical Trial.

52

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.

Dimitriou F, Orloff MM, Koch Hein EC, Cheng PF, Hughes IF, Simeone E, Montazeri K, Grover P, Mehmi I, Gerard CL, Gaudy-Marqueste C, Grob JJ, Michielin O, Hamid O, Long GV, Sullivan R, Kapiteijn E, Johnson DB, Ascierto PA, Joshua AM, Carvajal RD, Butler MO, Hassel JC, Dummer R. Dimitriou F, et al. Among authors: carvajal rd. Eur J Cancer. 2025 Jan;214:115161. doi: 10.1016/j.ejca.2024.115161. Epub 2024 Nov 30. Eur J Cancer. 2025. PMID: 39647344 Free article.

53

Radiotherapy after surgical resection for head and neck mucosal melanoma.

Wu AJ, Gomez J, Zhung JE, Chan K, Gomez DR, Wolden SL, Zelefsky MJ, Wolchok JD, Carvajal RD, Chapman PB, Wong RJ, Shaha AR, Kraus DH, Shah JP, Lee NY. Wu AJ, et al. Among authors: carvajal rd. Am J Clin Oncol. 2010 Jun;33(3):281-5. doi: 10.1097/COC.0b013e3181a879f5. Am J Clin Oncol. 2010. PMID: 19823070

54

Treatment implications of the emerging molecular classification system for melanoma.

Romano E, Schwartz GK, Chapman PB, Wolchock JD, Carvajal RD. Romano E, et al. Among authors: carvajal rd. Lancet Oncol. 2011 Sep;12(9):913-22. doi: 10.1016/S1470-2045(10)70274-6. Epub 2011 Feb 23. Lancet Oncol. 2011. PMID: 21349766 Review.

55

Treatment of locally recurrent mucosal melanoma with topical imiquimod.

Smyth EC, Flavin M, Pulitzer MP, Gardner GJ, Costantino PD, Chi DS, Bogatch K, Chapman PB, Wolchok JD, Schwartz GK, Carvajal RD. Smyth EC, et al. Among authors: carvajal rd. J Clin Oncol. 2011 Nov 20;29(33):e809-11. doi: 10.1200/JCO.2011.36.8829. Epub 2011 Oct 17. J Clin Oncol. 2011. PMID: 22010009 No abstract available.

56

Mucosal melanoma: a clinically and biologically unique disease entity.

Carvajal RD, Spencer SA, Lydiatt W. Carvajal RD, et al. J Natl Compr Canc Netw. 2012 Mar;10(3):345-56. doi: 10.6004/jnccn.2012.0034. J Natl Compr Canc Netw. 2012. PMID: 22393195 Review.

57

Therapeutic implications of KIT in melanoma.

Postow MA, Carvajal RD. Postow MA, et al. Among authors: carvajal rd. Cancer J. 2012 Mar-Apr;18(2):137-41. doi: 10.1097/PPO.0b013e31824b2404. Cancer J. 2012. PMID: 22453014 Review.

58

Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.

Ambrosini G, Pratilas CA, Qin LX, Tadi M, Surriga O, Carvajal RD, Schwartz GK. Ambrosini G, et al. Among authors: carvajal rd. Clin Cancer Res. 2012 Jul 1;18(13):3552-61. doi: 10.1158/1078-0432.CCR-11-3086. Epub 2012 May 1. Clin Cancer Res. 2012. PMID: 22550165 Free PMC article.

59

Unstable angina associated with cisplatin and carboplatin in a patient with advanced melanoma.

Khan S, Chen CL, Brady MS, Parameswaran R, Moore R, Hassoun H, Carvajal RD. Khan S, et al. Among authors: carvajal rd. J Clin Oncol. 2012 Jun 20;30(18):e163-4. doi: 10.1200/JCO.2011.38.7852. Epub 2012 May 14. J Clin Oncol. 2012. PMID: 22585705 No abstract available.

60

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.

Ott PA, Carvajal RD, Pandit-Taskar N, Jungbluth AA, Hoffman EW, Wu BW, Bomalaski JS, Venhaus R, Pan L, Old LJ, Pavlick AC, Wolchok JD. Ott PA, et al. Among authors: carvajal rd. Invest New Drugs. 2013 Apr;31(2):425-34. doi: 10.1007/s10637-012-9862-2. Epub 2012 Aug 5. Invest New Drugs. 2013. PMID: 22864522 Free PMC article. Clinical Trial.

61

Anal versus rectal melanoma: does site of origin predict outcome?

Bello DM, Smyth E, Perez D, Khan S, Temple LK, Ariyan CE, Weiser MR, Carvajal RD. Bello DM, et al. Among authors: carvajal rd. Dis Colon Rectum. 2013 Feb;56(2):150-7. doi: 10.1097/DCR.0b013e31827901dd. Dis Colon Rectum. 2013. PMID: 23303142 Free PMC article.

62

Another option in our KIT of effective therapies for advanced melanoma.

Carvajal RD. Carvajal RD. J Clin Oncol. 2013 Sep 10;31(26):3173-5. doi: 10.1200/JCO.2013.50.3144. Epub 2013 Aug 12. J Clin Oncol. 2013. PMID: 23940226 No abstract available.

63

Melanoma mutagenesis and aberrant cell signaling.

Bello DM, Ariyan CE, Carvajal RD. Bello DM, et al. Among authors: carvajal rd. Cancer Control. 2013 Oct;20(4):261-81. doi: 10.1177/107327481302000404. Cancer Control. 2013. PMID: 24077403 Free article. Review.

64

Selecting patients for KIT inhibition in melanoma.

Carvajal RD, Hamid O, Antonescu CR. Carvajal RD, et al. Methods Mol Biol. 2014;1102:137-62. doi: 10.1007/978-1-62703-727-3_9. Methods Mol Biol. 2014. PMID: 24258978

65

Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review.

Johnson DB, Peng C, Abramson RG, Ye F, Zhao S, Wolchok JD, Sosman JA, Carvajal RD, Ariyan CE. Johnson DB, et al. Among authors: carvajal rd. Oncologist. 2015 Jun;20(6):648-52. doi: 10.1634/theoncologist.2014-0468. Epub 2015 May 11. Oncologist. 2015. PMID: 25964307 Free PMC article.

66

A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma.

Shoushtari AN, Ong LT, Schoder H, Singh-Kandah S, Abbate KT, Postow MA, Callahan MK, Wolchok J, Chapman PB, Panageas KS, Schwartz GK, Carvajal RD. Shoushtari AN, et al. Among authors: carvajal rd. Melanoma Res. 2016 Jun;26(3):272-7. doi: 10.1097/CMR.0000000000000234. Melanoma Res. 2016. PMID: 26795274 Free PMC article. Clinical Trial.

67

Clinical utility of nivolumab in the treatment of advanced melanoma.

Asmar R, Yang J, Carvajal RD. Asmar R, et al. Among authors: carvajal rd. Ther Clin Risk Manag. 2016 Feb 26;12:313-25. doi: 10.2147/TCRM.S78039. eCollection 2016. Ther Clin Risk Manag. 2016. PMID: 27013881 Free PMC article. Review.

68

Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response.

Samstein RM, Carvajal RD, Postow MA, Callahan MK, Shoushtari AN, Patel SG, Lee NY, Barker CA. Samstein RM, et al. Among authors: carvajal rd. Head Neck. 2016 Sep;38(9):1310-7. doi: 10.1002/hed.24435. Epub 2016 Apr 4. Head Neck. 2016. PMID: 27043023 Free PMC article.

69

Uveal melanoma: epidemiology, etiology, and treatment of primary disease.

Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD. Krantz BA, et al. Among authors: carvajal rd. Clin Ophthalmol. 2017 Jan 31;11:279-289. doi: 10.2147/OPTH.S89591. eCollection 2017. Clin Ophthalmol. 2017. PMID: 28203054 Free PMC article. Review.

70

Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers.

Komatsubara KM, Jeter J, Carvajal RD, Margolin K, Schadendorf D, Hauschild A. Komatsubara KM, et al. Among authors: carvajal rd. Am Soc Clin Oncol Educ Book. 2017;37:641-650. doi: 10.1200/EDBK_175265. Am Soc Clin Oncol Educ Book. 2017. PMID: 28561682 Free article. Review.

71

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT. Sullivan RJ, et al. Among authors: carvajal rd. Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15. Cancer Discov. 2018. PMID: 29247021 Clinical Trial.

72

JAK-ing up the Response to KIT Inhibition.

Yang J, Komatsubara KM, Carvajal RD. Yang J, et al. Among authors: carvajal rd. J Invest Dermatol. 2018 Jan;138(1):6-8. doi: 10.1016/j.jid.2017.09.003. J Invest Dermatol. 2018. PMID: 29273148 Free article.

73

Chemoreduction of Orbital Recurrence of Uveal Melanoma by Intra-Arterial Melphalan.

Francis JH, Barker CA, Yin VT, Carvajal RD, Chapman P, Abramson DH, Gobin YP. Francis JH, et al. Among authors: carvajal rd. Ocul Oncol Pathol. 2019 Apr;5(3):186-189. doi: 10.1159/000490061. Epub 2018 Oct 9. Ocul Oncol Pathol. 2019. PMID: 31049326 Free PMC article.

74

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members; Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV. Amaria RN, et al. Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Lancet Oncol. 2019. PMID: 31267972 Review.

75

Novel Targets for the Treatment of Melanoma.

Ambrosi L, Khan S, Carvajal RD, Yang J. Ambrosi L, et al. Among authors: carvajal rd. Curr Oncol Rep. 2019 Nov 6;21(11):97. doi: 10.1007/s11912-019-0849-4. Curr Oncol Rep. 2019. PMID: 31696329 Review.

76

Advances in Prevention and Surveillance of Cutaneous Malignancies.

Trager MH, Queen D, Samie FH, Carvajal RD, Bickers DR, Geskin LJ. Trager MH, et al. Among authors: carvajal rd. Am J Med. 2020 Apr;133(4):417-423. doi: 10.1016/j.amjmed.2019.10.008. Epub 2019 Nov 9. Am J Med. 2020. PMID: 31712100 Free PMC article. Review.

77

Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy).

Ascierto PA, Puzanov I, Agarwala SS, Blank C, Carvajal RD, Demaria S, Dummer R, Ernstoff M, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Lo RS, Long GV, Luke JJ, Osman I, Postow MA, Sullivan RJ, Taube JM, Trinchieri G, Zarour HM, Caracò C, Thurin M. Ascierto PA, et al. Among authors: carvajal rd. J Transl Med. 2020 Sep 7;18(1):346. doi: 10.1186/s12967-020-02482-x. J Transl Med. 2020. PMID: 32894202 Free PMC article.

78

Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement.

Al-Adra DP, Hammel L, Roberts J, Woodle ES, Levine D, Mandelbrot D, Verna E, Locke J, D'Cunha J, Farr M, Sawinski D, Agarwal PK, Plichta J, Pruthi S, Farr D, Carvajal R, Walker J, Zwald F, Habermann T, Gertz M, Bierman P, Dizon DS, Langstraat C, Al-Qaoud T, Eggener S, Richgels JP, Chang GJ, Geltzeiler C, Sapisochin G, Ricciardi R, Krupnick AS, Kennedy C, Mohindra N, Foley DP, Watt KD. Al-Adra DP, et al. Am J Transplant. 2021 Feb;21(2):460-474. doi: 10.1111/ajt.16318. Epub 2020 Oct 23. Am J Transplant. 2021. PMID: 32969590 Free PMC article. Review.

79

Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement.

Al-Adra DP, Hammel L, Roberts J, Woodle ES, Levine D, Mandelbrot D, Verna E, Locke J, D'Cunha J, Farr M, Sawinski D, Agarwal PK, Plichta J, Pruthi S, Farr D, Carvajal R, Walker J, Zwald F, Habermann T, Gertz M, Bierman P, Dizon DS, Langstraat C, Al-Qaoud T, Eggener S, Richgels JP, Chang GJ, Geltzeiler C, Sapisochin G, Ricciardi R, Krupnick AS, Kennedy C, Mohindra N, Foley DP, Watt KD. Al-Adra DP, et al. Am J Transplant. 2021 Feb;21(2):475-483. doi: 10.1111/ajt.16324. Epub 2020 Oct 10. Am J Transplant. 2021. PMID: 32976703 Free PMC article.

80

Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence.

Stonesifer CJ, Djavid AR, Grimes JM, Khaleel AE, Soliman YS, Maisel-Campbell A, Garcia-Saleem TJ, Geskin LJ, Carvajal RD. Stonesifer CJ, et al. Among authors: carvajal rd. Front Oncol. 2021 Dec 20;11:734354. doi: 10.3389/fonc.2021.734354. eCollection 2021. Front Oncol. 2021. PMID: 34988009 Free PMC article. Review.

81

The reporting of uveal melanoma cases to the cancer registry in North Carolina.

Gordon KG, Carvajal RD, Graham SL, Houghton OM. Gordon KG, et al. Among authors: carvajal rd. Front Oncol. 2022 Aug 3;12:877599. doi: 10.3389/fonc.2022.877599. eCollection 2022. Front Oncol. 2022. PMID: 35992848 Free PMC article.

82

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).

Ascierto PA, Agarwala SS, Blank C, Caracò C, Carvajal RD, Ernstoff MS, Ferrone S, Fox BA, Gajewski TF, Garbe C, Grob JJ, Hamid O, Krogsgaard M, Lo RS, Lund AW, Madonna G, Michielin O, Neyns B, Osman I, Peters S, Poulikakos PI, Quezada SA, Reinfeld B, Zitvogel L, Puzanov I, Thurin M. Ascierto PA, et al. Among authors: carvajal rd. J Transl Med. 2022 Sep 4;20(1):391. doi: 10.1186/s12967-022-03592-4. J Transl Med. 2022. PMID: 36058945 Free PMC article.

83

KIT as a therapeutic target in metastatic melanoma.

Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. Carvajal RD, et al. JAMA. 2011 Jun 8;305(22):2327-34. doi: 10.1001/jama.2011.746. JAMA. 2011. PMID: 21642685 Free PMC article. Clinical Trial.

84

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.

Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD, Egberts F, Hauschild A, Kashani-Sabet M, Goldinger SM, Dummer R, Long GV, McArthur G, Scherag A, Sucker A, Schadendorf D. Zimmer L, et al. Among authors: carvajal rd. J Clin Oncol. 2012 Jul 1;30(19):2375-83. doi: 10.1200/JCO.2011.41.1660. Epub 2012 May 21. J Clin Oncol. 2012. PMID: 22614973 Free PMC article.

85

Ipilimumab for patients with advanced mucosal melanoma.

Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD. Postow MA, et al. Among authors: carvajal rd. Oncologist. 2013 Jun;18(6):726-32. doi: 10.1634/theoncologist.2012-0464. Epub 2013 May 28. Oncologist. 2013. PMID: 23716015 Free PMC article.

86

Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy.

Harding JJ, Barker CA, Carvajal RD, Wolchok JD, Chapman PB, Lacouture ME. Harding JJ, et al. Among authors: carvajal rd. J Clin Oncol. 2014 May 10;32(14):e54-6. doi: 10.1200/JCO.2013.49.3528. Epub 2014 Jan 27. J Clin Oncol. 2014. PMID: 24470011 Free PMC article. No abstract available.

87

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS. Topalian SL, et al. Among authors: carvajal rd. J Clin Oncol. 2014 Apr 1;32(10):1020-30. doi: 10.1200/JCO.2013.53.0105. Epub 2014 Mar 3. J Clin Oncol. 2014. PMID: 24590637 Free PMC article. Clinical Trial.

88

Treatments for noncutaneous melanoma.

Khalil DN, Carvajal RD. Khalil DN, et al. Among authors: carvajal rd. Hematol Oncol Clin North Am. 2014 Jun;28(3):507-21. doi: 10.1016/j.hoc.2014.02.006. Hematol Oncol Clin North Am. 2014. PMID: 24880944 Review.

89

A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.

Carvajal RD, Wong MK, Thompson JA, Gordon MS, Lewis KD, Pavlick AC, Wolchok JD, Rojas PB, Schwartz JD, Bedikian AY. Carvajal RD, et al. Eur J Cancer. 2014 Aug;50(12):2099-107. doi: 10.1016/j.ejca.2014.03.289. Epub 2014 Jun 12. Eur J Cancer. 2014. PMID: 24930625 Free PMC article. Clinical Trial.

90

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.

Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD, Chapman PB, Sullivan RJ, Teitcher JB, Ramaiya N, Giobbie-Hurder A, Antonescu CR, Heinrich MC, Bastian BC, Corless CL, Fletcher JA, Hodi FS. Carvajal RD, et al. Clin Cancer Res. 2015 May 15;21(10):2289-96. doi: 10.1158/1078-0432.CCR-14-1630. Epub 2015 Feb 18. Clin Cancer Res. 2015. PMID: 25695690 Free PMC article. Clinical Trial.

91

Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.

Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR, Berry EG, Iafrate AJ, Sullivan RJ, Carvajal RD, Sosman JA. Johnson DB, et al. Among authors: carvajal rd. Cancer Immunol Res. 2015 Mar;3(3):288-295. doi: 10.1158/2326-6066.CIR-14-0207. Cancer Immunol Res. 2015. PMID: 25736262 Free PMC article.

92

A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.

Harding JJ, Catalanotti F, Munhoz RR, Cheng DT, Yaqubie A, Kelly N, McDermott GC, Kersellius R, Merghoub T, Lacouture ME, Carvajal RD, Panageas KS, Berger MF, Rosen N, Solit DB, Chapman PB. Harding JJ, et al. Among authors: carvajal rd. Oncologist. 2015 Jul;20(7):789-97. doi: 10.1634/theoncologist.2014-0012. Epub 2015 May 8. Oncologist. 2015. PMID: 25956405 Free PMC article. Clinical Trial.

93

Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB. Horvat TZ, et al. Among authors: carvajal rd. J Clin Oncol. 2015 Oct 1;33(28):3193-8. doi: 10.1200/JCO.2015.60.8448. Epub 2015 Aug 17. J Clin Oncol. 2015. PMID: 26282644 Free PMC article.

94

Reply to A. Indini et al.

Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB. Horvat TZ, et al. Among authors: carvajal rd. J Clin Oncol. 2016 Mar 20;34(9):1018-9. doi: 10.1200/JCO.2015.65.7007. Epub 2016 Jan 19. J Clin Oncol. 2016. PMID: 26786917 No abstract available.

95

The promise and challenges of rare cancer research.

Komatsubara KM, Carvajal RD. Komatsubara KM, et al. Among authors: carvajal rd. Lancet Oncol. 2016 Feb;17(2):136-138. doi: 10.1016/S1470-2045(15)00485-4. Lancet Oncol. 2016. PMID: 26868336 No abstract available.

96

Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.

Gulati N, Carvajal RD, Postow MA, Wolchok JD, Krueger JG. Gulati N, et al. Among authors: carvajal rd. Exp Dermatol. 2016 Jul;25(7):553-4. doi: 10.1111/exd.13030. Exp Dermatol. 2016. PMID: 27061281 Free PMC article. No abstract available.

97

Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.

Shoushtari AN, Bluth MJ, Goldman DA, Bitas C, Lefkowitz RA, Postow MA, Munhoz RR, Buchar G, Hester RH, Romero JA, Fitzpatrick LJ, Weiser MR, Panageas KS, Wolchok JD, Chapman PB, Carvajal RD. Shoushtari AN, et al. Among authors: carvajal rd. Melanoma Res. 2017 Feb;27(1):57-64. doi: 10.1097/CMR.0000000000000306. Melanoma Res. 2017. PMID: 27792058 Free PMC article.

98

A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma.

D'Angelo SP, Hamid OA, Tarhini A, Schadendorf D, Chmielowski B, Collichio FA, Pavlick AC, Lewis KD, Weil SC, Heyburn J, Schweizer C, O'Shannessy DJ, Carvajal RD. D'Angelo SP, et al. Among authors: carvajal rd. Invest New Drugs. 2018 Feb;36(1):103-113. doi: 10.1007/s10637-017-0530-4. Epub 2017 Nov 11. Invest New Drugs. 2018. PMID: 29127533 Free PMC article. Clinical Trial.

99

Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma.

Damato BE, Dukes J, Goodall H, Carvajal RD. Damato BE, et al. Among authors: carvajal rd. Cancers (Basel). 2019 Jul 11;11(7):971. doi: 10.3390/cancers11070971. Cancers (Basel). 2019. PMID: 31336704 Free PMC article. Review.

100

MicroRNA-based risk scoring system to identify early-stage oral squamous cell carcinoma patients at high-risk for cancer-specific mortality.

Yoon AJ, Wang S, Kutler DI, Carvajal RD, Philipone E, Wang T, Peters SM, LaRoche D, Hernandez BY, McDowell BD, Stewart CR, Momen-Heravi F, Santella RM. Yoon AJ, et al. Among authors: carvajal rd. Head Neck. 2020 Aug;42(8):1699-1712. doi: 10.1002/hed.26089. Epub 2020 Jan 25. Head Neck. 2020. PMID: 31981257 Free PMC article.

101

Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial.

Ahmed FS, Dercle L, Goldmacher GV, Yang H, Connors D, Tang Y, Karovic S, Zhao B, Carvajal RD, Robert C, Maitland ML, Oxnard GR, Schwartz LH. Ahmed FS, et al. Among authors: carvajal rd. Eur Radiol. 2021 Apr;31(4):1853-1862. doi: 10.1007/s00330-020-07249-y. Epub 2020 Sep 30. Eur Radiol. 2021. PMID: 32995974 Free PMC article. Clinical Trial.

102

Analysis of malignant melanoma risk and outcomes in solid organ transplant recipients: Assessment of transplant candidacy and the potential role of checkpoint inhibitors.

Zwald F, Carvajal RD, Walker J, Sawinski D, Al-Adra D. Zwald F, et al. Among authors: carvajal rd. Clin Transplant. 2021 May;35(5):e14264. doi: 10.1111/ctr.14264. Epub 2021 Mar 11. Clin Transplant. 2021. PMID: 33709489

103

Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.

Jung S, Armstrong E, Wei AZ, Ye F, Lee A, Carlino MS, Sullivan RJ, Carvajal RD, Shoushtari AN, Johnson DB. Jung S, et al. Among authors: carvajal rd. Br J Cancer. 2022 Nov;127(9):1726-1732. doi: 10.1038/s41416-022-01942-z. Epub 2022 Aug 23. Br J Cancer. 2022. PMID: 35999272 Free PMC article.

104

Dropped head syndrome: report of three cases during treatment with a MEK inhibitor.

Chen X, Schwartz GK, DeAngelis LM, Kaley T, Carvajal RD. Chen X, et al. Among authors: carvajal rd. Neurology. 2012 Oct 30;79(18):1929-31. doi: 10.1212/WNL.0b013e318271f87e. Epub 2012 Oct 17. Neurology. 2012. PMID: 23077008 Free PMC article. Clinical Trial. No abstract available.

105

Programmed death 1 immune checkpoint inhibitors.

Trivedi MS, Hoffner B, Winkelmann JL, Abbott ME, Hamid O, Carvajal RD. Trivedi MS, et al. Among authors: carvajal rd. Clin Adv Hematol Oncol. 2015 Dec;13(12):858-68. Clin Adv Hematol Oncol. 2015. PMID: 27058852 Review.

106

Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma.

Gartrell-Corrado RD, Chen AX, Rizk EM, Marks DK, Bogardus MH, Hart TD, Silverman AM, Bayan CY, Finkel GG, Barker LW, Komatsubara KM, Carvajal RD, Horst BA, Chang R, Monod A, Rabadan R, Saenger YM. Gartrell-Corrado RD, et al. Among authors: carvajal rd. Cancer Res. 2020 Mar 1;80(5):1078-1087. doi: 10.1158/0008-5472.CAN-19-2039. Epub 2020 Jan 16. Cancer Res. 2020. PMID: 31948941 Free PMC article.

107

FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With Pembrolizumab.

Yeh R, Trager MH, Rizk EM, Finkel GG, Barker LW, Carvajal RD, Geskin LJ, Schwartz GK, Schwartz L, Dercle L, Saenger YM. Yeh R, et al. Among authors: carvajal rd. Clin Nucl Med. 2020 Apr;45(4):267-275. doi: 10.1097/RLU.0000000000002967. Clin Nucl Med. 2020. PMID: 32108700 Free PMC article.

108

MicroRNA-Based Cancer Mortality Risk Scoring System and hTERT Expression in Early-Stage Oral Squamous Cell Carcinoma.

Yoon AJ, Santella RM, Wang S, Kutler DI, Carvajal RD, Philipone E, Wang T, Peters SM, Stewart CR, Momen-Heravi F, Troob S, Levin M, AkhavanAghdam Z, Shackelford AJ, Canterbury CR, Shimonosono M, Hernandez BY, McDowell BD, Nakagawa H. Yoon AJ, et al. Among authors: carvajal rd. J Oncol. 2021 Jan 15;2021:8292453. doi: 10.1155/2021/8292453. eCollection 2021. J Oncol. 2021. PMID: 33510789 Free PMC article.

109

Clinical Utilization, Utility, and Reimbursement for Expanded Genomic Panel Testing in Adult Oncology.

Hsiao SJ, Sireci AN, Pendrick D, Freeman C, Fernandes H, Schwartz GK, Henick BS, Mansukhani MM, Roth KA, Carvajal RD, Oberg JA. Hsiao SJ, et al. Among authors: carvajal rd. JCO Precis Oncol. 2020 Nov;4:1038-1048. doi: 10.1200/PO.20.00048. JCO Precis Oncol. 2020. PMID: 35050771

110

A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.

Lin CC, Garralda E, Schöffski P, Hong DS, Siu LL, Martin M, Maur M, Hui R, Soo RA, Chiu J, Zhang T, Ma B, Kyi C, Tan DS, Cassier PA, Sarantopoulos J, Weickhardt A, Carvajal RD, Spratlin J, Esaki T, Rolland F, Akerley W, Deschler-Baier B, Rispoli L, Samant TS, Chowdhury NR, Gusenleitner D, Kwak EL, Askoxylakis V, De Braud F. Lin CC, et al. Among authors: carvajal rd. Oncoimmunology. 2023 Dec 20;13(1):2290787. doi: 10.1080/2162402X.2023.2290787. eCollection 2024. Oncoimmunology. 2023. PMID: 38170160 Free PMC article. Clinical Trial.

111

Ipilimumab-induced colitis on FDG PET/CT.

Lyall A, Vargas HA, Carvajal RD, Ulaner G. Lyall A, et al. Among authors: carvajal rd. Clin Nucl Med. 2012 Jun;37(6):629-30. doi: 10.1097/RLU.0b013e318248549a. Clin Nucl Med. 2012. PMID: 22614208

112

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Drilon A, Wolchok JD, Carvajal RD, McHenry MB, Hosein F, Harbison CT, Grosso JF, Sznol M. Topalian SL, et al. Among authors: carvajal rd. JAMA Oncol. 2019 Oct 1;5(10):1411-1420. doi: 10.1001/jamaoncol.2019.2187. JAMA Oncol. 2019. PMID: 31343665 Free PMC article.

113

Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis.

Van Egeren D, Kohli K, Warner JL, Bedard PL, Riely G, Lepisto E, Schrag D, LeNoue-Newton M, Catalano P, Kehl KL, Michor F; AACR Project GENIE Consortium represented by Shawn Sweeney. Van Egeren D, et al. Sci Rep. 2022 Nov 9;12(1):19055. doi: 10.1038/s41598-022-21448-1. Sci Rep. 2022. PMID: 36351964 Free PMC article.

114

Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract.

Schiavone MB, Broach V, Shoushtari AN, Carvajal RD, Alektiar K, Kollmeier MA, Abu-Rustum NR, Leitao MM Jr. Schiavone MB, et al. Among authors: carvajal rd. Gynecol Oncol Rep. 2016 Apr 14;16:42-6. doi: 10.1016/j.gore.2016.04.001. eCollection 2016 Apr. Gynecol Oncol Rep. 2016. PMID: 27331137 Free PMC article.

115

Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond.

Chen LN, Carvajal RD. Chen LN, et al. Among authors: carvajal rd. Ann Transl Med. 2023 Aug 30;11(10):368. doi: 10.21037/atm-23-839. Epub 2023 Mar 13. Ann Transl Med. 2023. PMID: 37675306 Free PMC article. No abstract available.

116

Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.

Catalanotti F, Solit DB, Pulitzer MP, Berger MF, Scott SN, Iyriboz T, Lacouture ME, Panageas KS, Wolchok JD, Carvajal RD, Schwartz GK, Rosen N, Chapman PB. Catalanotti F, et al. Among authors: carvajal rd. Clin Cancer Res. 2013 Apr 15;19(8):2257-64. doi: 10.1158/1078-0432.CCR-12-3476. Epub 2013 Feb 26. Clin Cancer Res. 2013. PMID: 23444215 Free PMC article. Clinical Trial.

117

Evaluating Chemotherapy at the End of Life.

Provenzano AF, Carvajal RD. Provenzano AF, et al. Among authors: carvajal rd. JAMA Oncol. 2016 Jan;2(1):142-3. doi: 10.1001/jamaoncol.2015.4105. JAMA Oncol. 2016. PMID: 26767555 No abstract available.

118

Would the Recommended Dose Have Been Different Using Novel Dose-Finding Designs? Comparing Dose-Finding Designs in Published Trials.

Silva RB, Yap C, Carvajal R, Lee SM. Silva RB, et al. JCO Precis Oncol. 2021 Jun 15;5:PO.21.00136. doi: 10.1200/PO.21.00136. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34250415 Free PMC article.

119

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.

Rogiers A, Pires da Silva I, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, Zubiri L, Manos M, Bowling P, Elkrief A, Papneja N, Vitale MG, Rose AAN, Borgers JSW, Roy S, Mangana J, Pimentel Muniz T, Cooksley T, Lupu J, Vaisman A, Saibil SD, Butler MO, Menzies AM, Carlino MS, Erdmann M, Berking C, Zimmer L, Schadendorf D, Pala L, Queirolo P, Posch C, Hauschild A, Dummer R, Haanen J, Blank CU, Robert C, Sullivan RJ, Ascierto PA, Miller WH Jr, Stephen Hodi F, Suijkerbuijk KPM, Reynolds KL, Rahma OE, Lorigan PC, Carvajal RD, Lo S, Mandala M, Long GV. Rogiers A, et al. Among authors: carvajal rd. J Immunother Cancer. 2021 Jan;9(1):e001931. doi: 10.1136/jitc-2020-001931. J Immunother Cancer. 2021. PMID: 33468556 Free PMC article.

120

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.

Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Ku GY, et al. Among authors: carvajal rd. Cancer. 2010 Apr 1;116(7):1767-75. doi: 10.1002/cncr.24951. Cancer. 2010. PMID: 20143434 Free PMC article.

121

Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation.

Morales RE, Shoushtari AN, Walsh MM, Grewal P, Lipson EJ, Carvajal RD. Morales RE, et al. Among authors: carvajal rd. J Immunother Cancer. 2015 Jun 16;3:22. doi: 10.1186/s40425-015-0066-0. eCollection 2015. J Immunother Cancer. 2015. PMID: 26082835 Free PMC article.

122

Use of antibody arrays to probe exosome and extracellular vesicle mediated functional changes in cells.

Ambrosini G, Ebert B, Carvajal RD, Schwartz GK, Rai AJ. Ambrosini G, et al. Among authors: carvajal rd. Methods Enzymol. 2020;645:43-53. doi: 10.1016/bs.mie.2020.09.003. Epub 2020 Oct 1. Methods Enzymol. 2020. PMID: 33565977

123

Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.

Ginsberg BA, Gallardo HF, Rasalan TS, Adamow M, Mu Z, Tandon S, Bewkes BB, Roman RA, Chapman PB, Schwartz GK, Carvajal RD, Panageas KS, Terzulli SL, Houghton AN, Yuan JD, Wolchok JD. Ginsberg BA, et al. Among authors: carvajal rd. Clin Cancer Res. 2010 Aug 1;16(15):4057-65. doi: 10.1158/1078-0432.CCR-10-1093. Epub 2010 Jul 20. Clin Cancer Res. 2010. PMID: 20647477 Free PMC article. Clinical Trial.

124

Patient perspectives on ipilimumab across the melanoma treatment trajectory.

Shuk E, Shoushtari AN, Luke J, Postow MA, Callahan M, Harding JJ, Roth KG, Flavin M, Granobles A, Christian J, Gold G, Schoenhammer M, Gordon M, Cimaglia N, Dyson R, Goodman-Davis N, Colgan MN, Jefferson IS, Munhoz R, D'Angelo S, Wolchok J, Chapman P, Chi P, Carvajal RD, Hay JL. Shuk E, et al. Among authors: carvajal rd. Support Care Cancer. 2017 Jul;25(7):2155-2167. doi: 10.1007/s00520-017-3621-z. Epub 2017 Mar 1. Support Care Cancer. 2017. PMID: 28247127 Free PMC article.

125

Pembrolizumab and tavokinogene telseplasmid electroporation in metastatic melanoma.

Dollin Y, Rubin J, Carvajal RD, Rached H, Nitzkorski JR. Dollin Y, et al. Among authors: carvajal rd. Int J Surg Case Rep. 2020;77:591-594. doi: 10.1016/j.ijscr.2020.11.063. Epub 2020 Nov 16. Int J Surg Case Rep. 2020. PMID: 33395852 Free PMC article.

126

A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery.

Rosenbaum E, Chugh R, Ryan CW, Agulnik M, Milhem MM, George S, Jones RL, Chmielowski B, Van Tine BA, Tawbi H, Elias AD, Read WL, Budd GT, Qin LX, Rodler ET, Hirman J, Weiden P, Bennett CM, Livingston PO, Ragupathi G, Hansen D, D'Angelo SP, Tap WD, Schwartz GK, Maki RG, Carvajal RD. Rosenbaum E, et al. Among authors: carvajal rd. Eur J Cancer. 2022 Nov;176:155-163. doi: 10.1016/j.ejca.2022.09.003. Epub 2022 Oct 8. Eur J Cancer. 2022. PMID: 36215947 Free PMC article. Clinical Trial.

127

Melanoma driver mutations and immune therapy.

Johnson DB, Lovly CM, Sullivan RJ, Carvajal RD, Sosman JA. Johnson DB, et al. Among authors: carvajal rd. Oncoimmunology. 2016 Mar 10;5(5):e1051299. doi: 10.1080/2162402X.2015.1051299. eCollection 2016 May. Oncoimmunology. 2016. PMID: 27467925 Free PMC article.

128

OncoTree: A Cancer Classification System for Precision Oncology.

Kundra R, Zhang H, Sheridan R, Sirintrapun SJ, Wang A, Ochoa A, Wilson M, Gross B, Sun Y, Madupuri R, Satravada BA, Reales D, Vakiani E, Al-Ahmadie HA, Dogan A, Arcila M, Zehir A, Maron S, Berger MF, Viaplana C, Janeway K, Ducar M, Sholl L, Dogan S, Bedard P, Surrey LF, Sanchez IH, Syed A, Rema AB, Chakravarty D, Suehnholz S, Nissan M, Iyer GV, Murali R, Bouvier N, Soslow RA, Hyman D, Younes A, Intlekofer A, Harding JJ, Carvajal RD, Sabbatini PJ, Abou-Alfa GK, Morris L, Janjigian YY, Gallagher MM, Soumerai TA, Mellinghoff IK, Hakimi AA, Fury M, Huse JT, Bagrodia A, Hameed M, Thomas S, Gardos S, Cerami E, Mazor T, Kumari P, Raman P, Shivdasani P, MacFarland S, Newman S, Waanders A, Gao J, Solit D, Schultz N. Kundra R, et al. Among authors: carvajal rd. JCO Clin Cancer Inform. 2021 Feb;5:221-230. doi: 10.1200/CCI.20.00108. JCO Clin Cancer Inform. 2021. PMID: 33625877 Free PMC article.

129

Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies.

Brown S, Lavery JA, Shen R, Martin AS, Kehl KL, Sweeney SM, Lepisto EM, Rizvi H, McCarthy CG, Schultz N, Warner JL, Park BH, Bedard PL, Riely GJ, Schrag D, Panageas KS; AACR Project GENIE Consortium. Brown S, et al. JAMA Oncol. 2022 Feb 1;8(2):287-291. doi: 10.1001/jamaoncol.2021.5153. JAMA Oncol. 2022. PMID: 34734967 Free PMC article.

130

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.

Schöffski P, Tan DSW, Martín M, Ochoa-de-Olza M, Sarantopoulos J, Carvajal RD, Kyi C, Esaki T, Prawira A, Akerley W, De Braud F, Hui R, Zhang T, Soo RA, Maur M, Weickhardt A, Krauss J, Deschler-Baier B, Lau A, Samant TS, Longmire T, Chowdhury NR, Sabatos-Peyton CA, Patel N, Ramesh R, Hu T, Carion A, Gusenleitner D, Yerramilli-Rao P, Askoxylakis V, Kwak EL, Hong DS. Schöffski P, et al. Among authors: carvajal rd. J Immunother Cancer. 2022 Feb;10(2):e003776. doi: 10.1136/jitc-2021-003776. J Immunother Cancer. 2022. PMID: 35217575 Free PMC article. Clinical Trial.

131

DQueST: dynamic questionnaire for search of clinical trials.

Liu C, Yuan C, Butler AM, Carvajal RD, Li ZR, Ta CN, Weng C. Liu C, et al. Among authors: carvajal rd. J Am Med Inform Assoc. 2019 Nov 1;26(11):1333-1343. doi: 10.1093/jamia/ocz121. J Am Med Inform Assoc. 2019. PMID: 31390010 Free PMC article.

132

Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2).

Sun J, Gastman BR, McCahon L, Buchbinder EI, Puzanov I, Nanni M, Lewis JM, Carvajal RD, Singh-Kandah S, Desai AM, Raskin L, Nielson CM, Ismail R, Zager JS. Sun J, et al. Among authors: carvajal rd. Melanoma Manag. 2020 Jun 15;7(2):MMT41. doi: 10.2217/mmt-2020-0005. Melanoma Manag. 2020. PMID: 32821373 Free PMC article.

133

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Topalian SL, et al. Among authors: carvajal rd. N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2. N Engl J Med. 2012. PMID: 22658127 Free PMC article. Clinical Trial.

134

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, Brahmer JR. Gettinger SN, et al. Among authors: carvajal rd. J Clin Oncol. 2015 Jun 20;33(18):2004-12. doi: 10.1200/JCO.2014.58.3708. Epub 2015 Apr 20. J Clin Oncol. 2015. PMID: 25897158 Free PMC article. Clinical Trial.

135

Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid.

Beck KM, Dong J, Geskin LJ, Beltrani VP, Phelps RG, Carvajal RD, Schwartz G, Saenger YM, Gartrell RD. Beck KM, et al. Among authors: carvajal rd. J Immunother Cancer. 2016 Apr 19;4:20. doi: 10.1186/s40425-016-0123-3. eCollection 2016. J Immunother Cancer. 2016. PMID: 27096097 Free PMC article.

136

Cellular therapy for the treatment of solid tumors.

Grimes JM, Carvajal RD, Muranski P. Grimes JM, et al. Among authors: carvajal rd. Transfus Apher Sci. 2021 Feb;60(1):103056. doi: 10.1016/j.transci.2021.103056. Epub 2021 Jan 10. Transfus Apher Sci. 2021. PMID: 33478888 Review.

137

Arginine depletion as a therapeutic approach for patients with COVID-19.

Grimes JM, Khan S, Badeaux M, Rao RM, Rowlinson SW, Carvajal RD. Grimes JM, et al. Among authors: carvajal rd. Int J Infect Dis. 2021 Jan;102:566-570. doi: 10.1016/j.ijid.2020.10.100. Epub 2020 Nov 4. Int J Infect Dis. 2021. PMID: 33160064 Free PMC article. Review.

138

Ipilimumab in patients with melanoma and autoimmune disease.

Kyi C, Carvajal RD, Wolchok JD, Postow MA. Kyi C, et al. Among authors: carvajal rd. J Immunother Cancer. 2014 Oct 14;2(1):35. doi: 10.1186/s40425-014-0035-z. eCollection 2014. J Immunother Cancer. 2014. PMID: 25349698 Free PMC article.

139

Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.

Hamid O, Hoffner B, Gasal E, Hong J, Carvajal RD. Hamid O, et al. Among authors: carvajal rd. Cancer Immunol Immunother. 2017 Oct;66(10):1249-1264. doi: 10.1007/s00262-017-2025-8. Epub 2017 Jul 15. Cancer Immunol Immunother. 2017. PMID: 28712033 Free PMC article. Review.

140

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma.

Hamid O, Cowey CL, Offner M, Faries M, Carvajal RD. Hamid O, et al. Among authors: carvajal rd. Cancers (Basel). 2019 Oct 24;11(11):1642. doi: 10.3390/cancers11111642. Cancers (Basel). 2019. PMID: 31653096 Free PMC article.

141

First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors.

Bauer T, Cho BC, Heist R, Bazhenova L, Werner T, Goel S, Kim DW, Adkins D, Carvajal RD, Alva A, Eaton K, Wang J, Liu Y, Yan X, Christensen J, Neuteboom S, Chao R, Pant S. Bauer T, et al. Among authors: carvajal rd. Invest New Drugs. 2022 Oct;40(5):990-1000. doi: 10.1007/s10637-022-01274-y. Epub 2022 Jun 29. Invest New Drugs. 2022. PMID: 35767205 Free PMC article. Clinical Trial.

142

The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial.

Luke JJ, D'Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Maki RG, de Stanchina E, Musi E, Singer S, Schwartz GK. Luke JJ, et al. Among authors: carvajal rd. Clin Cancer Res. 2012 May 1;18(9):2638-47. doi: 10.1158/1078-0432.CCR-11-3203. Epub 2012 Feb 28. Clin Cancer Res. 2012. PMID: 22374332 Free PMC article. Clinical Trial.

143

Aurora kinases: new targets for cancer therapy.

Carvajal RD, Tse A, Schwartz GK. Carvajal RD, et al. Clin Cancer Res. 2006 Dec 1;12(23):6869-75. doi: 10.1158/1078-0432.CCR-06-1405. Clin Cancer Res. 2006. PMID: 17145803 Review.

144

A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.

Dickson MA, Shah MA, Rathkopf D, Tse A, Carvajal RD, Wu N, Lefkowitz RA, Gonen M, Cane LM, Dials HJ, Schwartz GK. Dickson MA, et al. Among authors: carvajal rd. Cancer Chemother Pharmacol. 2010 Nov;66(6):1113-21. doi: 10.1007/s00280-010-1269-1. Epub 2010 Feb 21. Cancer Chemother Pharmacol. 2010. PMID: 20953860 Free PMC article. Clinical Trial.

145

The promise and pitfalls of the many methods of plasma genotyping.

Komatsubara KM, Carvajal RD, Sacher AG. Komatsubara KM, et al. Among authors: carvajal rd. Expert Opin Biol Ther. 2016 Nov;16(11):1313-1316. doi: 10.1080/14712598.2016.1229769. Epub 2016 Sep 12. Expert Opin Biol Ther. 2016. PMID: 27608417 No abstract available.

146

Perspectives on the recommendations for skin cancer management during the COVID-19 pandemic.

Geskin LJ, Trager MH, Aasi SZ, Bickers DR, Carvajal RD, Nghiem P, Taback B, Zeitouni NC, Samie FH. Geskin LJ, et al. Among authors: carvajal rd. J Am Acad Dermatol. 2020 Jul;83(1):295-296. doi: 10.1016/j.jaad.2020.05.002. Epub 2020 May 6. J Am Acad Dermatol. 2020. PMID: 32387656 Free PMC article. No abstract available.

147

A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors.

Dickson MA, Carvajal RD, Merrill AH Jr, Gonen M, Cane LM, Schwartz GK. Dickson MA, et al. Among authors: carvajal rd. Clin Cancer Res. 2011 Apr 15;17(8):2484-92. doi: 10.1158/1078-0432.CCR-10-2323. Epub 2011 Jan 21. Clin Cancer Res. 2011. PMID: 21257722 Free PMC article. Clinical Trial.

148

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, Brahmer JR, Carvajal RD, Hammers HJ, Puzanov I, Hodi FS, Kluger HM, Topalian SL, Pardoll DM, Wigginton JM, Kollia GD, Gupta A, McDonald D, Sankar V, Sosman JA, Atkins MB. McDermott DF, et al. Among authors: carvajal rd. J Clin Oncol. 2015 Jun 20;33(18):2013-20. doi: 10.1200/JCO.2014.58.1041. Epub 2015 Mar 30. J Clin Oncol. 2015. PMID: 25800770 Free PMC article. Clinical Trial.

149

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors.

Tran B, Carvajal RD, Marabelle A, Patel SP, LoRusso PM, Rasmussen E, Juan G, Upreti VV, Beers C, Ngarmchamnanrith G, Schöffski P. Tran B, et al. Among authors: carvajal rd. J Immunother Cancer. 2018 Sep 25;6(1):93. doi: 10.1186/s40425-018-0407-x. J Immunother Cancer. 2018. PMID: 30253804 Free PMC article. Clinical Trial.

150

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies.

Papadopoulos KP, Johnson ML, Lockhart AC, Moore K, Falchook GS, Formenti SC, Naing A, Carvajal RD, Rosen LS, Weiss GJ, Leidner RS, Li J, Paccaly A, Feng M, Stankevich E, Lowy I, Fury MG, Crittenden MR. Papadopoulos KP, et al. Among authors: carvajal rd. Clin Cancer Res. 2020 Mar 1;26(5):1025-1033. doi: 10.1158/1078-0432.CCR-19-2609. Epub 2019 Dec 3. Clin Cancer Res. 2020. PMID: 31796520 Clinical Trial.

151

A Case Report of Papillary Digital Adenocarcinoma With BRAFV600E Mutation and Quantified Mutational Burden.

Trager MH, Jurkiewicz M, Khan S, Niedt GW, Geskin LJ, Carvajal RD. Trager MH, et al. Among authors: carvajal rd. Am J Dermatopathol. 2021 Jan 1;43(1):57-59. doi: 10.1097/DAD.0000000000001694. Am J Dermatopathol. 2021. PMID: 32568833

152

Ewing's sarcoma and primitive neuroectodermal family of tumors.

Carvajal R, Meyers P. Carvajal R, et al. Hematol Oncol Clin North Am. 2005 Jun;19(3):501-25, vi-vii. doi: 10.1016/j.hoc.2005.03.004. Hematol Oncol Clin North Am. 2005. PMID: 15939194 Review.

153

Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus.

Schrock AB, Pavlick D, Klempner SJ, Chung JH, Forcier B, Welsh A, Young L, Leyland-Jones B, Bordoni R, Carvajal RD, Chao J, Kurzrock R, Sicklick JK, Ross JS, Stephens PJ, Devoe C, Braiteh F, Ali SM, Miller VA. Schrock AB, et al. Among authors: carvajal rd. Clin Cancer Res. 2018 Apr 15;24(8):1881-1890. doi: 10.1158/1078-0432.CCR-17-3103. Epub 2018 Jan 23. Clin Cancer Res. 2018. PMID: 29363525 Free PMC article.

154

A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.

Dickson MA, Rathkopf DE, Carvajal RD, Grant S, Roberts JD, Reid JM, Ames MM, McGovern RM, Lefkowitz RA, Gonen M, Cane LM, Dials HJ, Schwartz GK. Dickson MA, et al. Among authors: carvajal rd. Invest New Drugs. 2011 Oct;29(5):1004-12. doi: 10.1007/s10637-010-9447-x. Epub 2010 May 12. Invest New Drugs. 2011. PMID: 20461440 Free PMC article. Clinical Trial.

155

A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular Carcinoma.

Ang C, O'Reilly EM, Carvajal RD, Capanu M, Gonen M, Doyle L, Ghossein R, Schwartz L, Jacobs G, Ma J, Schwartz GK, Abou-Alfa GK. Ang C, et al. Among authors: carvajal rd. Gastrointest Cancer Res. 2012 Nov;5(6):185-9. Gastrointest Cancer Res. 2012. PMID: 23293699 Free PMC article.

156

A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors.

Diaz LA Jr, Coughlin CM, Weil SC, Fishel J, Gounder MM, Lawrence S, Azad N, O'Shannessy DJ, Grasso L, Wustner J, Ebel W, Carvajal RD. Diaz LA Jr, et al. Among authors: carvajal rd. Clin Cancer Res. 2015 Mar 15;21(6):1281-8. doi: 10.1158/1078-0432.CCR-14-1829. Epub 2014 Nov 14. Clin Cancer Res. 2015. PMID: 25398449 Free PMC article. Clinical Trial.

157

Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors.

Rathkopf D, Dickson MA, Feldman DR, Carvajal RD, Shah MA, Wu N, Lefkowitz R, Gonen M, Cane LM, Dials HJ, Winkelmann JL, Bosl GJ, Schwartz GK. Rathkopf D, et al. Among authors: carvajal rd. Clin Cancer Res. 2009 Dec 1;15(23):7405-11. doi: 10.1158/1078-0432.CCR-09-1502. Epub 2009 Nov 24. Clin Cancer Res. 2009. PMID: 19934304 Free PMC article. Clinical Trial.

158

A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors.

D'Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Hensley ML, Hirst CM, Ezeoke MO, Ahn L, Qin LX, Antonescu CR, Lefkowitz RA, Maki RG, Schwartz GK, Tap WD. D'Adamo DR, et al. Among authors: carvajal rd. Oncologist. 2019 Jun;24(6):857-863. doi: 10.1634/theoncologist.2018-0160. Epub 2018 Aug 20. Oncologist. 2019. PMID: 30126857 Free PMC article. Clinical Trial.

159

Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial.

Chung DJ, Carvajal RD, Postow MA, Sharma S, Pronschinske KB, Shyer JA, Singh-Kandah S, Dickson MA, D'Angelo SP, Wolchok JD, Young JW. Chung DJ, et al. Among authors: carvajal rd. Oncoimmunology. 2017 Sep 21;7(1):e1372081. doi: 10.1080/2162402X.2017.1372081. eCollection 2017. Oncoimmunology. 2017. PMID: 29296525 Free PMC article.

160

A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.

Falchook GS, Peeters M, Rottey S, Dirix LY, Obermannova R, Cohen JE, Perets R, Frommer RS, Bauer TM, Wang JS, Carvajal RD, Sabari J, Chapman S, Zhang W, Calderon B, Peterson DA. Falchook GS, et al. Among authors: carvajal rd. Invest New Drugs. 2021 Oct;39(5):1284-1297. doi: 10.1007/s10637-021-01088-4. Epub 2021 Apr 14. Invest New Drugs. 2021. PMID: 33852104 Clinical Trial.

161

Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific.

Sacco JJ, Kirk P, Leach E, Shoushtari AN, Carvajal RD, Britton-Rivet C, Khakoo S, Collins L, de la Cruz-Merino L, Eroglu Z, Ikeguchi AP, Nathan P, Hamid O, Butler MO, Stanhope S, Ranade K, Sato T. Sacco JJ, et al. Among authors: carvajal rd. Cell Rep Med. 2025 Apr 15;6(4):102076. doi: 10.1016/j.xcrm.2025.102076. Cell Rep Med. 2025. PMID: 40239619 Clinical Trial.

162

Intramedullary primary spinal cord melanoma: illustrative case.

Mishra A, Golub D, Schneider D, Garrel S, Shah HA, Mehta SH, Sistiaga IL, Li JY, Ramlal B, Singer S, Carvajal RD, Sciubba DM, Lo SL. Mishra A, et al. Among authors: carvajal rd. J Neurosurg Case Lessons. 2025 Mar 10;9(10):CASE24732. doi: 10.3171/CASE24732. Print 2025 Mar 10. J Neurosurg Case Lessons. 2025. PMID: 40063999 Free PMC article.

163

Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma.

Yoon AJ, Carvajal RD, Graboyes EM, Kaczmar JM, Albergotti WG, Kejner AE, Troob SH, Philipone E, Anoma JS, Armeson KE, Hill EG, Richardson MS, Woods TR, Chera BS, Nourollah-Zadeh F, Lee BJ, Pandruvada S, Kourtidis A, Kingsley C, O'Quinn EC, Mills S, Jordan VC, Spencer M, Fails D, McKee TD, Zaidi M, Brisendine A, Horn S, Mehrotra S, Ogretmen B, Newman JG. Yoon AJ, et al. Among authors: carvajal rd. Front Immunol. 2025 Jan 27;16:1530262. doi: 10.3389/fimmu.2025.1530262. eCollection 2025. Front Immunol. 2025. PMID: 39931064 Free PMC article. Clinical Trial.

164

Dose Individualization for Phase I Cancer Trials With Broadened Eligibility.

Silva RB, Cheng B, Carvajal RD, Lee SM. Silva RB, et al. Among authors: carvajal rd. Stat Med. 2024 Dec 20;43(29):5534-5547. doi: 10.1002/sim.10264. Epub 2024 Oct 31. Stat Med. 2024. PMID: 39479896

165

Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023.

Seedor RS, Aplin AE, Bertolotto C, Carvajal RD, Deacon N, Doble K, Hamid O, Haq R, Kadosh M, Khan S, Kraska J, Lutzky J, McKean M, Montazeri K, Moser J, Onken M, Orloff M, Sacco JJ, Smalley K, Selig SM. Seedor RS, et al. Among authors: carvajal rd. Pigment Cell Melanoma Res. 2025 Jan;38(1):e13205. doi: 10.1111/pcmr.13205. Epub 2024 Oct 9. Pigment Cell Melanoma Res. 2025. PMID: 39385554 Free PMC article.

166

Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion.

Watt KD, Rolak S, Foley DP, Plichta JK, Pruthi S, Farr D, Zwald FO, Carvajal RD, Dudek AZ, Sanger CB, Rocco R, Chang GJ, Dizon DS, Langstraat CL, Teoh D, Agarwal PK, Al-Qaoud T, Eggener S, Kennedy CC, D'Cunha J, Mohindra NA, Stewart S, Habermann TH, Schuster S, Lunning M, Shah NN, Gertz MA, Mehta J, Suvannasankha A, Verna E, Farr M, Blosser CD, Hammel L, Al-Adra DP. Watt KD, et al. Among authors: carvajal rd. Transplantation. 2024 Dec 1;108(12):2336-2350. doi: 10.1097/TP.0000000000005056. Epub 2024 May 21. Transplantation. 2024. PMID: 38771067 Review.

167

Updates in the Management of Uveal Melanoma.

Barbi M, Carvajal RD, Devoe CE. Barbi M, et al. Among authors: carvajal rd. Cancer J. 2024 Mar-Apr 01;30(2):92-101. doi: 10.1097/PPO.0000000000000708. Cancer J. 2024. PMID: 38527262 Review.

168

Editorial: Non-cutaneous melanoma: new therapeutic insights.

Rossi E, Carvajal RD. Rossi E, et al. Among authors: carvajal rd. Front Oncol. 2024 Jan 17;13:1362238. doi: 10.3389/fonc.2023.1362238. eCollection 2023. Front Oncol. 2024. PMID: 38298444 Free PMC article. No abstract available.

169

Diversifying Eligibility to Enhance Real-World Results.

Fayyaz F, Carvajal RD, Devoe CE. Fayyaz F, et al. Among authors: carvajal rd. J Clin Oncol. 2023 Aug 10;41(23):3895-3898. doi: 10.1200/JCO.23.00836. Epub 2023 Jun 12. J Clin Oncol. 2023. PMID: 37307516 No abstract available.

170

Scoping review of genetic databases for rare dermatologic diseases: Opportunity for artificial intelligence and machine learning.

Schreidah CM, Reynolds GB, Fahmy LM, Carvajal RD, Vermeer MH, Whittaker S, Pe'er I, Geskin LJ. Schreidah CM, et al. Among authors: carvajal rd. JAAD Int. 2023 Mar 31;12:24-31. doi: 10.1016/j.jdin.2023.02.017. eCollection 2023 Sep. JAAD Int. 2023. PMID: 37228361 Free PMC article. No abstract available.

171

A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies.

Mundi PS, Dela Cruz FS, Grunn A, Diolaiti D, Mauguen A, Rainey AR, Guillan K, Siddiquee A, You D, Realubit R, Karan C, Ortiz MV, Douglass EF, Accordino M, Mistretta S, Brogan F, Bruce JN, Caescu CI, Carvajal RD, Crew KD, Decastro G, Heaney M, Henick BS, Hershman DL, Hou JY, Iwamoto FM, Jurcic JG, Kiran RP, Kluger MD, Kreisl T, Lamanna N, Lassman AB, Lim EA, Manji GA, McKhann GM, McKiernan JM, Neugut AI, Olive KP, Rosenblat T, Schwartz GK, Shu CA, Sisti MB, Tergas A, Vattakalam RM, Welch M, Wenske S, Wright JD, Canoll P, Hibshoosh H, Kalinsky K, Aburi M, Sims PA, Alvarez MJ, Kung AL, Califano A. Mundi PS, et al. Among authors: carvajal rd. Cancer Discov. 2023 Jun 2;13(6):1386-1407. doi: 10.1158/2159-8290.CD-22-1020. Cancer Discov. 2023. PMID: 37061969 Free PMC article.

172

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.

Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS. Topalian SL, et al. Among authors: carvajal rd. J Clin Oncol. 2023 Feb 10;41(5):943-954. doi: 10.1200/JCO.22.02272. J Clin Oncol. 2023. PMID: 36750016 Clinical Trial.

173

Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens.

Wang Y, Fan JL, Melms JC, Amin AD, Georgis Y, Barrera I, Ho P, Tagore S, Abril-Rodríguez G, He S, Jin Y, Biermann J, Hofree M, Caprio L, Berhe S, Khan SA, Henick BS, Ribas A, Macosko EZ, Chen F, Taylor AM, Schwartz GK, Carvajal RD, Azizi E, Izar B. Wang Y, et al. Among authors: carvajal rd. Nat Genet. 2023 Jan;55(1):19-25. doi: 10.1038/s41588-022-01268-9. Epub 2023 Jan 9. Nat Genet. 2023. PMID: 36624340 Free PMC article.

174

A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma.

Piperno-Neumann S, Carlino MS, Boni V, Loirat D, Speetjens FM, Park JJ, Calvo E, Carvajal RD, Nyakas M, Gonzalez-Maffe J, Zhu X, Shirley MD, Ramkumar T, Fessehatsion A, Burks HE, Yerramilli-Rao P, Kapiteijn E. Piperno-Neumann S, et al. Among authors: carvajal rd. Br J Cancer. 2023 Apr;128(6):1040-1051. doi: 10.1038/s41416-022-02133-6. Epub 2023 Jan 9. Br J Cancer. 2023. PMID: 36624219 Free PMC article. Clinical Trial.

175

Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification.

Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Fu S, et al. Among authors: carvajal rd. J Clin Oncol. 2023 Mar 20;41(9):1725-1734. doi: 10.1200/JCO.22.00830. Epub 2022 Dec 5. J Clin Oncol. 2023. PMID: 36469840 Free PMC article. Clinical Trial.

176

Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.

Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi A, Hernandez-Aya L, Nathan P, Hamid O, Piulats JM, Rioth M, Johnson DB, Luke JJ, Espinosa E, Leyvraz S, Collins L, Goodall HM, Ranade K, Holland C, Abdullah SE, Sacco JJ, Sato T. Carvajal RD, et al. Nat Med. 2022 Nov;28(11):2364-2373. doi: 10.1038/s41591-022-02015-7. Epub 2022 Oct 13. Nat Med. 2022. PMID: 36229663 Free PMC article. Clinical Trial.

177

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.

Dimitriou F, Namikawa K, Reijers ILM, Buchbinder EI, Soon JA, Zaremba A, Teterycz P, Mooradian MJ, Armstrong E, Nakamura Y, Vitale MG, Tran LE, Bai X, Allayous C, Provent-Roy S, Indini A, Bhave P, Farid M, Kähler KC, Mehmi I, Atkinson V, Klein O, Stonesifer CJ, Zaman F, Haydon A, Carvajal RD, Hamid O, Dummer R, Hauschild A, Carlino MS, Mandala M, Robert C, Lebbe C, Guo J, Johnson DB, Ascierto PA, Shoushtari AN, Sullivan RJ, Cybulska-Stopa B, Rutkowski P, Zimmer L, Sandhu S, Blank CU, Lo SN, Menzies AM, Long GV. Dimitriou F, et al. Among authors: carvajal rd. Ann Oncol. 2022 Sep;33(9):968-980. doi: 10.1016/j.annonc.2022.06.004. Epub 2022 Jun 16. Ann Oncol. 2022. PMID: 35716907 Free article.

178

Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors.

Goldman JW, Piha-Paul SA, Curti B, Pedersen KS, Bauer TM, Groenland SL, Carvajal RD, Chhaya V, Kirby G, McGlinchey K, Hammond SA, Streicher K, Townsley DM, Chae YK, Voortman J, Marabelle A, Powderly J. Goldman JW, et al. Among authors: carvajal rd. Clin Cancer Res. 2022 Sep 1;28(17):3709-3719. doi: 10.1158/1078-0432.CCR-21-3016. Clin Cancer Res. 2022. PMID: 35699623

179

Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.

Carvajal RD, Nathan P, Sacco JJ, Orloff M, Hernandez-Aya LF, Yang J, Luke JJ, Butler MO, Stanhope S, Collins L, McAlpine C, Holland C, Abdullah SE, Sato T. Carvajal RD, et al. J Clin Oncol. 2022 Jun 10;40(17):1939-1948. doi: 10.1200/JCO.21.01805. Epub 2022 Mar 7. J Clin Oncol. 2022. PMID: 35254876 Free PMC article. Clinical Trial.

180

New targeted and epigenetic therapeutic strategies for the treatment of uveal melanoma.

Wei AZ, Maniar AB, Carvajal RD. Wei AZ, et al. Among authors: carvajal rd. Cancer Gene Ther. 2022 Dec;29(12):1819-1826. doi: 10.1038/s41417-022-00443-8. Epub 2022 Mar 2. Cancer Gene Ther. 2022. PMID: 35236928 Review.

181

A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma.

Shoushtari AN, Khan S, Komatsubara K, Feun L, Acquavella N, Singh-Kandah S, Negri T, Nesson A, Abbate K, Cremers S, Musi E, Ambrosini G, Lee S, Schwartz GK, Carvajal RD. Shoushtari AN, et al. Among authors: carvajal rd. Cancers (Basel). 2021 Nov 2;13(21):5504. doi: 10.3390/cancers13215504. Cancers (Basel). 2021. PMID: 34771668 Free PMC article.

182

LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.

Dowlati A, Harvey RD, Carvajal RD, Hamid O, Klempner SJ, Kauh JSW, Peterson DA, Yu D, Chapman SC, Szpurka AM, Carlsen M, Quinlan T, Wesolowski R. Dowlati A, et al. Among authors: carvajal rd. Invest New Drugs. 2021 Aug;39(4):1057-1071. doi: 10.1007/s10637-021-01084-8. Epub 2021 Feb 23. Invest New Drugs. 2021. PMID: 33624233 Clinical Trial.

183

OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.

Gutierrez M, Moreno V, Heinhuis KM, Olszanski AJ, Spreafico A, Ong M, Chu Q, Carvajal RD, Trigo J, Ochoa de Olza M, Provencio M, De Vos FY, De Braud F, Leong S, Lathers D, Wang R, Ravindran P, Feng Y, Aanur P, Melero I. Gutierrez M, et al. Among authors: carvajal rd. Clin Cancer Res. 2021 Jan 15;27(2):460-472. doi: 10.1158/1078-0432.CCR-20-1830. Epub 2020 Nov 4. Clin Cancer Res. 2021. PMID: 33148673 Free article. Clinical Trial.

184

Dual checkpoint inhibitor-associated eosinophilic enteritis.

Yang J, Lagana SM, Saenger YM, Carvajal RD. Yang J, et al. Among authors: carvajal rd. J Immunother Cancer. 2019 Nov 15;7(1):310. doi: 10.1186/s40425-019-0743-5. J Immunother Cancer. 2019. PMID: 31730503 Free PMC article.

185

An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors.

Wang R, Gao C, Raymond M, Dito G, Kabbabe D, Shao X, Hilt E, Sun Y, Pak I, Gutierrez M, Melero I, Spreafico A, Carvajal RD, Ong M, Olszanski AJ, Milburn C, Thudium K, Yang Z, Feng Y, Fracasso PM, Korman AJ, Aanur P, Huang SA, Quigley M. Wang R, et al. Among authors: carvajal rd. Clin Cancer Res. 2019 Nov 15;25(22):6709-6720. doi: 10.1158/1078-0432.CCR-19-0526. Epub 2019 Oct 1. Clin Cancer Res. 2019. PMID: 31573956 Clinical Trial.

186

Prognostic Value of Low Tumor Burden in Patients With Melanoma.

Poklepovic AS, Carvajal RD. Poklepovic AS, et al. Among authors: carvajal rd. Oncology (Williston Park). 2018 Sep 15;32(9):e90-e96. Oncology (Williston Park). 2018. PMID: 30248170 Free article. Review.

187

Secondary Prevention Strategies for Nonmelanoma Skin Cancer.

Lopez AT, Carvajal RD, Geskin L. Lopez AT, et al. Among authors: carvajal rd. Oncology (Williston Park). 2018 Apr 15;32(4):195-200. Oncology (Williston Park). 2018. PMID: 29684233 Free article. Review.

188

Mucosal Melanoma: New Insights and Therapeutic Options for a Unique and Aggressive Disease.

Lerner BA, Stewart LA, Horowitz DP, Carvajal RD. Lerner BA, et al. Among authors: carvajal rd. Oncology (Williston Park). 2017 Nov 15;31(11):e23-e32. Oncology (Williston Park). 2017. PMID: 29179253 Free article. Review.

189

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.

Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, Queirolo P, Arance A, Berking C, Camargo V, Herchenhorn D, Petrella TM, Schadendorf D, Sharfman W, Testori A, Novick S, Hertle S, Nourry C, Chen Q, Hodi FS. Guo J, et al. Among authors: carvajal rd. Ann Oncol. 2017 Jun 1;28(6):1380-1387. doi: 10.1093/annonc/mdx079. Ann Oncol. 2017. PMID: 28327988 Free PMC article. Clinical Trial.

190

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.

Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA Jr, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF. Soumerai JD, et al. Among authors: carvajal rd. Clin Cancer Res. 2017 Aug 1;23(15):4119-4126. doi: 10.1158/1078-0432.CCR-16-3068. Epub 2017 Mar 17. Clin Cancer Res. 2017. PMID: 28314788 Free PMC article. Clinical Trial.

191

Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.

D'Angelo SP, Shoushtari AN, Keohan ML, Dickson MA, Gounder MM, Chi P, Loo JK, Gaffney L, Schneider L, Patel Z, Erinjeri JP, Bluth MJ, Sjoberg A, Streicher H, Takebe N, Qin LX, Antonescu C, DeMatteo RP, Carvajal RD, Tap WD. D'Angelo SP, et al. Among authors: carvajal rd. Clin Cancer Res. 2017 Jun 15;23(12):2972-2980. doi: 10.1158/1078-0432.CCR-16-2349. Epub 2016 Dec 22. Clin Cancer Res. 2017. PMID: 28007774 Free PMC article. Clinical Trial.

192

A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.

Munhoz RR, D'Angelo SP, Gounder MM, Keohan ML, Chi P, Carvajal RD, Singer S, Crago AM, Landa J, Healey JH, Qin LX, Hameed M, Ezeoke MO, Singh AS, Agulnik M, Chmielowski B, Luke JJ, Van Tine BA, Schwartz GK, Tap WD, Dickson MA. Munhoz RR, et al. Among authors: carvajal rd. Oncologist. 2015 Nov;20(11):1245-6. doi: 10.1634/theoncologist.2015-0245. Epub 2015 Oct 8. Oncologist. 2015. PMID: 26449382 Free PMC article. Clinical Trial.

193

Corrigendum to "Sarcoma Immunotherapy: Past Approaches and Future Directions".

D'Angelo SP, Tap WD, Schwartz GK, Carvajal RD. D'Angelo SP, et al. Among authors: carvajal rd. Sarcoma. 2015;2015:259817. doi: 10.1155/2015/259817. Epub 2015 Jun 9. Sarcoma. 2015. PMID: 26180507 Free PMC article.

194

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma.

Dickson MA, D'Adamo DR, Keohan ML, D'Angelo SP, Carvajal RD, Gounder MM, Maki RG, Qin LX, Lefkowitz RA, McKennon OR, Hirst CM, Schwartz GK, Tap WD. Dickson MA, et al. Among authors: carvajal rd. Sarcoma. 2015;2015:532478. doi: 10.1155/2015/532478. Epub 2015 May 14. Sarcoma. 2015. PMID: 26074722 Free PMC article.

195

Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials.

Hyman DM, Eaton AA, Gounder MM, Pamer EG, Pettiford J, Carvajal RD, Ivy SP, Iasonos A, Spriggs DR. Hyman DM, et al. Among authors: carvajal rd. Oncotarget. 2015 Aug 7;6(22):19316-27. doi: 10.18632/oncotarget.2909. Oncotarget. 2015. PMID: 25682870 Free PMC article. Clinical Trial.

196

Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.

Hyman DM, Snyder AE, Carvajal RD, Gerecitano JF, Voss MH, Ho AL, Konner J, Winkelmann JL, Stasi MA, Monson KR, Iasonos A, Spriggs DR, Bialer P, Lacouture ME, Teitcher JB, Katabi N, Fury MG. Hyman DM, et al. Among authors: carvajal rd. Cancer Chemother Pharmacol. 2015 Apr;75(4):747-55. doi: 10.1007/s00280-015-2693-z. Epub 2015 Feb 12. Cancer Chemother Pharmacol. 2015. PMID: 25672916 Free PMC article. Clinical Trial.

197

Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.

D'Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Carvajal RD, Dickson MA, Gounder M, Keohan ML, Schwartz GK, Tap WD. D'Angelo SP, et al. Among authors: carvajal rd. Hum Pathol. 2015 Mar;46(3):357-65. doi: 10.1016/j.humpath.2014.11.001. Epub 2014 Nov 15. Hum Pathol. 2015. PMID: 25540867 Free PMC article.

198

Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe.

Phillips E, Penate-Medina O, Zanzonico PB, Carvajal RD, Mohan P, Ye Y, Humm J, Gönen M, Kalaigian H, Schöder H, Strauss HW, Larson SM, Wiesner U, Bradbury MS. Phillips E, et al. Among authors: carvajal rd. Sci Transl Med. 2014 Oct 29;6(260):260ra149. doi: 10.1126/scitranslmed.3009524. Epub 2014 Oct 29. Sci Transl Med. 2014. PMID: 25355699 Free PMC article. Clinical Trial.

199

Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients.

Belum VR, Rosen AC, Jaimes N, Dranitsaris G, Pulitzer MP, Busam KJ, Marghoob AA, Carvajal RD, Chapman PB, Lacouture ME. Belum VR, et al. Among authors: carvajal rd. Cancer. 2015 Jan 1;121(1):60-8. doi: 10.1002/cncr.28980. Epub 2014 Sep 3. Cancer. 2015. PMID: 25186461 Free article.

200

Sarcoma immunotherapy: past approaches and future directions.

D'Angelo SP, Tap WD, Schwartz GK, Carvajal RD. D'Angelo SP, et al. Among authors: carvajal rd. Sarcoma. 2014;2014:391967. doi: 10.1155/2014/391967. Epub 2014 Mar 20. Sarcoma. 2014. PMID: 24778572 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

208 results

Search Page

Filters